Keybank National Association OH Buys 5,794 Shares of AstraZeneca PLC (NASDAQ:AZN)

Keybank National Association OH raised its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 12.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 54,109 shares of the company's stock after purchasing an additional 5,794 shares during the quarter. Keybank National Association OH's holdings in AstraZeneca were worth $3,977,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Capital International Investors boosted its stake in shares of AstraZeneca by 1.9% during the 4th quarter. Capital International Investors now owns 37,507,159 shares of the company's stock worth $2,457,706,000 after acquiring an additional 686,008 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of AstraZeneca by 189.3% during the 4th quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock worth $1,574,247,000 after acquiring an additional 15,722,197 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of AstraZeneca by 1.9% during the 4th quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock worth $1,276,367,000 after acquiring an additional 357,894 shares in the last quarter. Sanders Capital LLC boosted its stake in shares of AstraZeneca by 1.4% during the 4th quarter. Sanders Capital LLC now owns 15,186,692 shares of the company's stock worth $995,032,000 after acquiring an additional 212,301 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of AstraZeneca by 13.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,322,388 shares of the company's stock worth $348,730,000 after acquiring an additional 636,537 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Stock Down 2.2%

Shares of AstraZeneca stock traded down $1.53 during midday trading on Friday, hitting $69.60. The company's stock had a trading volume of 6,768,010 shares, compared to its average volume of 5,264,380. The firm has a market capitalization of $215.85 billion, a P/E ratio of 27.95, a PEG ratio of 1.28 and a beta of 0.37. The stock has a 50-day simple moving average of $70.78 and a 200-day simple moving average of $70.64. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. The business had revenue of $13.59 billion during the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. AstraZeneca's revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.06 earnings per share. As a group, sell-side analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

Separately, BNP Paribas started coverage on AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $85.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.